The present study evaluates the prognostic value of 12-months levels of NT-proBNP and the estimated 12-month longitudinal change in NT-proBNP with respect to the onset of adverse CVE during nine years follow-up in patients with stable CHD. This evidence concerns the gene NPPB and coronary artery disorder.